Evaluation of the effects of additional therapy with Berberis vulgaris oxymel in patients with refractory primary sclerosing cholangitis and primary biliary cholangitis: A quasi-experimental study | ||
| Avicenna Journal of Phytomedicine | ||
| دوره 11، شماره 2، خرداد و تیر 2021، صفحه 154-167 اصل مقاله (619.82 K) | ||
| نوع مقاله: Original Research Article | ||
| شناسه دیجیتال (DOI): 10.22038/ajp.2020.16281 | ||
| نویسندگان | ||
| Zahra Naghibi1؛ Hassan Rakhshandeh2؛ Lida Jarahi3؛ Seyed Mousa Alreza Hosseini* 4؛ Mahdi Yousefi* 1 | ||
| 1Department of Persian Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| 2Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Iran; Department of Pharmacology, Faculty of Medicine, Mashhad University of Medical Sciences, Iran. | ||
| 3Department of Community Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| 4Department of internal Medicine, faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran; Surgical oncology research center, Mashhad University of Medical Science, Mashhad, Iran | ||
| چکیده | ||
| Objective: There are several studies reporting the therapeutic effects of Berberis vulgaris on liver diseases. This study was done with the purpose of examining the effect of B. vulgaris oxymel (BO) in patients with refractory primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), who did not respond to current treatment. Materials and Methods: Patients with PSC or PBC who were receiving ursodeoxycholic acid (UDCA, 13-15 mg/kg/day) for at least six months, but their serum levels of alkaline phosphatase (ALP) were still 1.5 folds higher than the normal upper limit during the last six months, were asked to participate in this quasi-experimental study. Patients were asked to take 0.5 ml/kg/day of BOtwo times a day for three months along with UDCA. At the end of the study, serum levels of ALP, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), total bilirubin (TB), direct bilirubin (DB), and creatinine as well as prothrombin time (PT), international normalized ratio (INR) and quality of life (QOL) based on PBC-40 questionnaire were assessed as outcomes. Results: Our results showed that BO notably attenuated the serum levels of ALP, AST, ALT, GGT, TB, and DB, as well as PT and INR and significantly improved QOL. Conclusion: For first time, we showed that additional therapy with BOhas a promising effect in the treatment of refractory PSC and PBC. | ||
| کلیدواژهها | ||
| Primary sclerosing cholangitis؛ Primary biliary cholangitis؛ Berberis vulgaris؛ Cholestasis؛ Alkaline phosphatase | ||
| مراجع | ||
|
Abd AE-W, Ghareeb DA, Sarhan E, Abu- Serie MM, El Demellawy MA. 2013. In vitro biological assessment of Berberis vulgaris and its active constituent, berberine: antioxidants, anti-acetylcholinesterase, antidiabetic and anticancer effects. BMC complement and alternate med, 13: 218. Angulo P, Jorgensen RA, Kowdley KV, Lindor KD. 2008. Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig Dis Sci, 53: 1716-1720. Angulo, Patel T, Jorgensen RA, Therneau TM, Lindor KD. 2000. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology, 32: 897- 900. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ. 2010. Diagnosis and management of primary sclerosing cholangitis. Hepatology, 51: 660-678. Corpechot C. 2012. Primary biliary cirrhosis and bile acids. Clin Res Hepatol Gastroenterol, 36: S13-S20. Dávalos A, Bartolomé B, Gómez-Cordovés C. 2005. Antioxidant properties of commercial grape juices and vinegars. Food chem, 93: 325-330. Eaton JE, Nelson KM, Gossard AA, Carey EJ, Tabibian JH, Lindor KD, Larusso NF. 2019. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study. Scand J Gastroenterol, 54(5): 633- 639. Ghorbani A, Mohebbati R, Jafarian AH, Vahedi MM, Hosseini SM, Soukhtanloo M, Sadeghnia HR. 2016. Toxicity evaluation of hydroalcoholic extract of Ferula gummosa root. Regul Toxicol Pharmacol, 77: 35-41. Hanachi P, Kua S, Asmah R, Motalleb G, Fauziah O. 2006. Cytotoxic effect of Berberis vulgaris fruit extract on the Naghibi et al. AJP, Vol. 11, No. 2, Mar-Apr 2021 164 proliferation of human liver cancer cell line (HepG2) and its antioxidant properties. Int J cancer res, 2: 1-9. Hosseini A, Mollazadeh H, Amiri MS, Sadeghnia HR, Ghorbani A. 2017. Effects of a standardized extract of Rheum turkestanicum Janischew root on diabetic changes in the kidney, liver and heart of streptozotocin-induced diabetic rats. Biomed Pharmacother, 86: 605-611. Kashkooli R, Najafi SS, Sharif F, Hamedi A, Hoseini As, Najafi Kalyani M, Birjandi M. 2015. The effect of berberis vulgaris extract on transaminase activities in non-alcoholic Fatty liver disease. Hepat Mon, 15: e25067- e25067. Imanshahidi M, Hosseinzadeh H. 2008. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res, 22: 999-1012. Khorasani SA. 1859. Gharabadin kabir, Tehran, Institute for the Study of Medical History and Islamic Medicine and compelmentary medicine. Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, Vincent C, Rust C, Pares A, Mason A. 2018. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology, 67: 1890- 1902. Lazaridis KN, Gores GJ, Lindor KD. 2001. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol, 35: 134-146. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. 2009. Primary biliary cirrhosis. Hepatology, 50: 291-308. Milkiewicz P, Wunsch E, Elias E. 2012. Liver transplantation in chronic cholestatic conditions. Front Biosci, 17: 959-969. Mirazi N, Tohidi F, Hosseini A. 2015. Effect of berberis vulgaris hydroethanolic extract on serum bilirubin level and liver enzymes in male cholstatic rats. Knowledge and Health, 10: 59-67. Motalleb G, Hanachi P, Kua S, Fauziah O, Asmah R. 2005. Evaluation of phenolic content and total antioxidant activity in Berberis vulgaris fruit extract. J Biol Sci, 5: 648-53. Pisonero-Vaquero S, González-Gallego J, Sánchez-Campos S, Victoria GarciaMediavilla M. 2015. Flavonoids and related compounds in non-alcoholic fatty liver disease therapy. Curr Med Chem, 22: 2991- 3012. Rahimi-Madiseh M, Karimian P, Kafeshani M, Rafieian-Kopaei M. 2017a. The effects of ethanol extract of Berberis vulgaris fruit on histopathological changes and biochemical markers of the liver damage in diabetic rats. Iran J Basic Med Sci, 20: 552-556. Rahimi-Madiseh M, Lorigoini Z, ZamaniGharaghoshi H, Rafiean-Kopaei M. 2017b. Berberis vulgaris: specifications and traditional uses. Iran J Basic Med Sci, 20: 569. Rodriguez -Ramiro I, Vauzour D, Minihane A. 2016. Polyphenols and non-alcoholic fatty liver disease: impact and mechanisms. Proc Nutr Soc, 75: 47-60. Samad A, Azlan A, Ismail A. 2016. Therapeutic effects of vinegar: a review. Curr Opin Food Sci, 8: 56-61 Wunsch E, Trottier J, Milkiewicz M, RaszejaWyszomirska, Hirschfiled GM, Barbier O, Milkiewicz P. 2014. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology, 60: 931-940. Zarei A, Changiz-Ashtiyani S, Taheri S, Ramezani M. 2015. A quick overview on some aspects of endocrinological and therapeutic effects of Berberis vulgaris L. Avicenna J Phytomed, 5: 485. Zargaran A, Zarshenas M, Mehdizadeh A, Mohagheghzadeh A. 2012. Oxymel in medi | ||
|
آمار تعداد مشاهده مقاله: 14,974 تعداد دریافت فایل اصل مقاله: 2,802 |
||